Dear All, BARDA is interested in hearing from antibiotic developers about antibiotics which could be used under Emergency Use Authorization (EUA) or marketing authorization for the treatment and/or PEP (post-exposure prophylaxis) of a biothreat indication, specifically: Y. pestis, F. tularensis, and/or B. pseudomallei. Here’s the core message from the pre-solicitation notice: Topline: “The U.S. Government

Dear All, I want to call your attention to the replay available on YouTube of the excellent 24 Sep 2020 webinar entitled “The global movement of microorganisms:Tracking the spread of difficult-to-treat infections.” Chair by Dame Sally, this 90-minute webinar (link) had 4 global speakers: (Geneva) Hanan Balkhy, Assistant Director-General, World Health Organization (Addis Ababa) John Nkengasong,

Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections due to resistant Gram-negative bacteria (link). 8 Apr 2021 update: IDSA have published an updated version of this document. It excellent to see IDSA working steadily to provide up-to-the-minute advice! 24 Nov 2021 update: IDSA